Court ruling on bluebird bio’s gene therapy marketing campaign 'sparks' dismay at Roche's Spark

In a blow to Roche, gene therapy developer bluebird bio can continue to use “spark” in its marketing campaign for sickle cell disease—at least for a while.

A federal judge in Delaware on Tuesday denied a request by Roche’s Spark Therapeutics unit for a preliminary injunction to temporarily block bluebird’s direct-to-consumer disease awareness project, dubbed “Be the Spark.”